氯沙坦对原发性高血压患者纤溶功能的影响

目的观察氯沙坦对原发性高血压(EH)患者纤溶功能的影响。方法观察34例EH患者应用氯沙坦治疗4周后收缩压(SBP)、舒张压(DBP)、心率、血浆组织型纤溶酶原激活物(t-PA)、内皮细胞型纤溶酶原激活物抑制剂(PAI-1)水平的变化,并与30例健康人作比较。结果治疗前EH患者血浆t-PA水平明显低于对照组,而PAI-1水平明显高于对照组(均P<0.01)。氯沙坦治疗4周后,血压明显下降,心率无明显变化,血浆t-PA水平增加,但无统计学意义,而PAI-1水平明显降低,t-PA/PAI-1比值升高(均P<0.01)。结论EH患者存在着内源性纤溶功能紊乱,氯沙坦可以改善EH患者的纤溶功能。

Effects of losartan therapy on fibrinolysis in essential hypertension patients

Objective To investigate the effects of losartan on fibrinolysis in 34 essential hypertension patients.Methods Thirty-four patients with essential hypertension were given losartan for 4 weeks.Systolic and diastolic blood pressure(SBP,DBP),heart rate(HR),concentration of plasminogen activator inhibitor(PAI-1) and tissue-type plasminogen activator(t-PA) were measured before and after losartan treatment.Thirty healthy persons were taken as control group.Results Before treatment,plasma t-PA level was lower and PAI-1 level was higher in hypertension group than in control group(P<0.01).After losartan treatment,the SBP and DBP were both significantly decreased(P<0.01) in hypertension group,while the HR and the t-PA level did not change.The PAI-1 level was decreased and the ratio of tPA/ PAI-1 was increased significantly(both P<0.01).Conclusions There is endogenous fibrinolysis disturbance in essential hypertension patients and losartan therapy can improve the fibrinolytic activity.